Pulmonary Metabolism of Resveratrol: In Vitro and In Vivo Evidence

Satish Sharan and Swati Nagar

Department of Pharmaceutical Sciences, Temple University School of Pharmacy, Philadelphia, Pennsylvania

Received January 30, 2013; accepted March 8, 2013

ABSTRACT

The role of pulmonary metabolism in trans-resveratrol (RES) pharmacokinetics was studied in a mouse model. Plasma concentrations of RES and its major metabolites trans-resveratrol-3-sulfate (R3S) and trans-resveratrol-3-glucuronide (R3G) were compared after administration of RES by intravenous (IV) and intra-arterial (IA) routes. Total area under the curve (AUC) of RES decreased by approximately 50% when RES was administered by the IV route compared with the IA route. The AUC of R3G was also significantly higher in mice administered RES by the IV route compared with the IA route. In vitro studies performed with mouse and human lung fractions confirmed pulmonary metabolism of RES. Interestingly, mouse-lung fractions gave rise to both R3S and R3G, whereas human lung fractions yielded R3S. This indicates marked interspecies variation in RES conjugation, especially in the context of extrapolating rodent data to humans. Taken together, the results presented here underline, for the first time, the impact of pulmonary metabolism on resveratrol pharmacokinetics and interspecies differences in RES pulmonary metabolism.

Introduction

The knowledge of extrahepatic metabolism in drug disposition is important. Extrahepatic drug metabolism can modify the systemic as well as tissue exposure of drug/metabolites, and this becomes especially important in cases of active metabolite formation and certain disease states. For example, in severe cirrhosis of the liver, extrahepatic metabolic pathways might compensate for the impaired hepatic elimination of a drug (Patwardhan et al., 1981). Tissue levels of drug/active metabolites might change, depending on the site of metabolism. For example, in the case of irinotecan, its active metabolite SN-38 (7-ethyl-10-hydroxy-camptothecin) is conjugated to SN-38 glucuronide in the liver, which is eliminated in the bile and metabolized by gut β-glucuronidase to regenerate SN-38. Locally formed SN-38 is thought to cause diarrhea (Araki et al., 1993; Takasuna et al., 1996; Michael et al., 2004). Thus, information about sites of metabolism is important for appropriately selecting a dosage regimen for various clinical conditions, as well as for selection of appropriate route of drug administration.

The route of drug administration can significantly change the disposition of parent drug and metabolites if extrahepatic eliminating organs are involved. Although a bioavailability of 100% is assumed on intravenous (IV) administration of a drug, pulmonary metabolism can decrease the bioavailability even on IV administration. Compounds administered orally must cross the gut and lungs in addition to the liver before reaching the arterial blood supply for distribution to tissues. The lung as a site of metabolism assumes significance as the entire cardiac output (approximately four times liver blood flow) perfuses the lung and can play an important role in drug disposition (Davies and Morris, 1993). It has been shown that phenolic compounds (e.g., harmol) (Mulder et al., 1984) and phenol (Cassidy and Houston, 1984) undergo pulmonary metabolism.

Trans-resveratrol (RES) is a dietary phytochemical known to have beneficial health effects via numerous mechanisms (Baur and Sinclair, 2006). RES induces apoptosis in human lung adenocarcinoma cells (Alex et al., 2010; Zhang et al., 2011; Zhang et al., 2012b). It also has lung cancer chemopreventive activity by altering the expression of genes involved in the phase 1 metabolism of polycyclic hydrocarbons (Mollerup et al., 2001). Although the role of the gut and liver is well known in the metabolism of RES (Kuhnle et al., 2000; Miksits et al., 2005; Brill et al., 2006; Iwuchukwu and Nagar, 2008; van de Wetering et al., 2009), the role of lungs has not been evaluated in the metabolism of RES. RES is known to be extensively metabolized into its two major metabolites [i.e., trans-resveratrol-3-sulfate (R3S) and trans-resveratrol-3-glucuronide (R3G)] (Fig. 1) in humans as well as in rodents (Yu et al., 2002; Meng et al., 2004; Hoshino et al., 2010; Sharan et al., 2012). A monosulfated metabolite of RES, R3S was recently shown to be biologically active in in vitro studies (Hoshino et al., 2010). Although glucuronides have generally been assumed to be pharmacologically inactive, examples do exist of active glucuronidated metabolites (Osborne et al., 1988; Kroemer and Klotz, 1989). The presence of pulmonary metabolites of RES suggests that the lung might be a site of RES metabolism.

This work was partially supported by awards from the National Institutes of Health (NIH) National Cancer Institute (NCI) [Grants R03CA133943 and R03CA159389]. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or NCI.

This work has been submitted as part of Satish Sharan’s Ph.D. thesis to Temple University.

dx.doi.org/10.1124/dmd.113.051326.

ABBREVIATIONS: APAP, acetaminophen; AUC, area under the curve; BCRP (uppercase), human breast cancer resistance protein; bcrp (lowercase), mouse protein; CL, clearance; HP-β-CD, 2-hydroxypropyl-β-cyclodextrin; IA, intra-arterial; IS, internal standard; IV, intravenous; LC-MS/MS, liquid chromatography with tandem mass spectrometry; MRP (uppercase), human multidrug resistance protein; mrp (lowercase), mouse protein; PAPS, 3′-phospho-adenosine-5′-phosphosulphate; QC, quality control; RES, trans-3,5,4′-trihydroxystilbene, trans-resveratrol; R3G, trans-resveratrol-3-O-glucuronide; R4G, trans-resveratrol-4′-O-glucuronide; R3S, trans-resveratrol-3-sulfate; R4S, trans-resveratrol-4′-sulfate; SN-38, 7-ethyl-10-hydroxy-camptothecin; SULT, sulfotransferase; SULT (uppercase), human protein; sul (lowercase), mouse protein; UGT, uridine 5′-diphosphoglucuronyltransferase; UGT (uppercase), human protein; ugt (lowercase), mouse protein; UDPGA, uridine 5′-diphosphoglucuronic acid; Vss, volume of distribution at steady state.

DRUG METABOLISM & DISPOSITION

Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics

http://dx.doi.org/10.1124/dmd.113.051326

Drug Metab Dispos 41:1163–1169, May 2013
Materials and Methods

Chemicals. RES was purchased from Cayman Chemicals (Ann Arbor, MI). R3S and R3G for calibration were purchased from Toronto Research Chemicals (North York, ON, Canada). The cofactors UDPGA and PAPS (3′-phosphoadenosine-5′-phosphosulfate) were purchased from Sigma-Aldrich (St. Louis, MO). Mouse and human lung fractions were purchased from XenoTech, LLC (Lenexa, KS). Other reagents were purchased from standard sources. All reagents for analytical procedures were of analytical grade.

Animals. Male C57BL/6 mice weighing between 20 and 25 g were supplied by Jackson Laboratory and maintained in the American Association for the Accreditation of Laboratory Animal Care–accredited University Laboratory Animal Resources of Temple University. Animals were fed a normal diet, and water was continuously available. Animals were housed in a standard 12-hour dark/light cycle and were acclimatized for 4 days before the procedure. Animals had free access to food and water during the procedure. All animal studies were approved by the Institutional Animal Care and Use Committee.

Catheterization. Right carotid artery and jugular vein cannulations were performed with the animals under anesthesia with EZ-ANESTHESIA apparatus (Sharan et al., 2012), we observed that murine systemic clearance of RES was higher than hepatic blood flow, indicating the possibility of extrahepatic conjugation in the mouse. These results led us to investigate the lung as a possible metabolizing organ for RES. We studied the contribution of the pulmonary metabolism of RES in vivo by using multiple sites of administration and a single site of sampling (Cassidy and Houston, 1980), which exploits the anatomic arrangement of lungs. When administered intravenously, RES enters the right atrium of the heart and crosses the lungs in a relatively undiluted form before reaching the general arterial system for distribution throughout the body. In contrast, with IA administration into the right carotid artery, RES is available immediately for tissue distribution. By comparison of plasma concentration time profiles after administration of RES by both routes, we calculated the contribution of lungs in the first-pass metabolism of RES across the lungs. In vivo findings in mice were further confirmed by in vitro experiments using lung fractions of mouse. Finally, in vitro studies using human lung fractions were also performed to compare mouse with human RES pulmonary conjugation.

Drug Administration and Blood Sampling. RES was solubilized in 20% 2-hydroxypropyl-β-cyclohextrim (HP-β-CD) in saline (Juan et al., 2010b). RES was administered by the IV route at a dose of 15 mg/kg. Carotid artery cannula was used for blood sampling. Heparin-saline (20 μl, 50 IU/ml) was used to flush the cannula after systemic administration or blood sampling. Blood (20 μl) was serially sampled at 2.5, 5, 10, 15, 45, 90, 180, 300, 420, and 600 minutes. Blood samples were centrifuged at 14,000 rpm for 2 minutes, and harvested plasma was collected and stored at −80°C until LC-MS/MS (liquid chromatography - tandem mass spectrometry) analysis. Experiment details of RES IA administration at dose of 15 mg/kg have been previously published (Sharan et al., 2012).

In Vitro Pulmonary Glucuronidation. RES glucuronidation was determined in pooled mouse lung S9 fraction and in pooled human lung microsomes. For mouse lung S9 glucuronidation assay, conditions of protein and time linearity were optimized in preliminary studies. Preliminary experiments showed that the reactions were linear up to 60 minutes and 2.5 mg/ml protein. The incubation mixture consisted of mouse lung S9 fraction (final concentration, 0.5 mg/ml), substrate RES (concentration ranging from 0.01 μM to 5 mM) solubilized in HP-β-CD (final HP-β-CD concentration 2%), alamethicin (final concentration 10 μg/ml), MgCl2 (final concentration 5 mM), and made up to final incubation volume of 500 μl with Tris-Cl buffer (100 mM, pH 7.4, 37°C). The reaction mixture was preincubated for 3 minutes in a shaking water bath at 37°C. The reaction was started by adding an appropriate volume of the cofactor UDPGA (uridine 5′-diphosphoglucuronic acid, final concentration 5 mM). To 20 μl of reaction mixture, 5 μl of ascorbic acid, and 60 μl of ice-cold methanol containing acetaminophen (APAP) as internal standard (IS) were added at the end of 60 minutes to stop the reaction. All reactions were performed in triplicate. Appropriate negative control experiments were performed under the same conditions but without UDPGA.

For the human lung glucuronidation assay, incubation was performed at 0.1, 0.5, and 2.5 mg/ml (final concentration) human lung microsomes with substrate RES (0.5 mM) solubilized in HP-β-CD (final HP-β-CD concentration 2%). Preliminary studies showed minimal glucuronidation in human lung microsomes; hence kinetic assays were not conducted.

In Vitro Pulmonary Sulfation. RES sulfation activity was determined in pooled mouse lung S9 fractions and in pooled human lung S9 fractions. Conditions of protein and time linearity were optimized in preliminary studies. Preliminary experiments showed that the reactions were linear up to 60 minutes and 2.5 mg/ml total protein for each protein source. The incubation mixture consisted of mouse lung S9 fractions (final concentration, 1 mg/ml) or human lung S9 fractions (final concentration, 0.5 mg/ml), the substrate RES (0.01 μM to 5 mM) solubilized in HP-β-CD (final HP-β-CD concentration 2%), MgCl2 (5 mM final concentration), and made up to final incubation volume of 500 μl with potassium phosphate buffer (10 mM, pH 6.5, 37°C). The reaction mixture was preincubated for 3 minutes in a shaking water bath at 37°C. The reaction was started by adding an appropriate volume of the cofactor UDPGA (final concentration, 1 mM) and incubated in a shaking water bath for 60 minutes at 37°C. To 20 μl of reaction mixture, 5 μl of ascorbic acid and 60 μl of ice-cold methanol containing acetaminophen (APAP; internal standard, or IS) were added at the end of 60 minutes to stop the reaction. All reactions were performed in triplicate. Appropriate negative control experiments were performed under the same conditions but without PAPS.

Protein Binding Assay. Equilibrium dialysis was performed using a 96-well equilibrium dialyzer with MW cutoff of 5K (Harvard Apparatus, Holliston, MA) and placed in dual-plate rotator set to maximum speed (Harvard Apparatus) placed in a 37°C incubator with 10% CO2 atmospheric environment. Frozen mouse plasma was thawed, and its pH was adjusted to 7.4. RES, R3S, and R3G plasma protein binding was determined at a concentration of 20 μM. The protein binding assay was performed with a published protocol (Kochansky et al., 2008).
LC-MS/MS Analysis. RES, R3G, and R3S concentrations in plasma and in
the in vitro reaction mixture were measured with an electrospray ionization
liquid chromatography-tandem mass spectrometry system (ABSciex API 4000;
Framingham, MA) set in negative ion scan mode as described previously
(Iwuchukwu et al., 2012). In brief, ascorbic acid (2.5 µl of a 15% solution) was
added to 10-µl plasma samples and vortexed for 1 minute. Then 30 µl of
methanol containing 78 ng/ml APAP (internal standard) was added and
vortexed for 1 minute and centrifuged at 15,000 rpm for 15 minutes at room
temperature. For in vitro studies, samples were prepared as described earlier
herein. Supernatant (10 µl) was injected into the liquid chromatography tandem
mass spectrometry system. The chromatographic separation system consisted of
a guard column (Zorbax SB-C18, 5 µm, 4.6 × 12.5 mm; Agilent Technologies,
Santa Clara, CA), an analytical column (Zorbax SB-C18, 5 µm, 4.6 × 150 mm;
Agilent Technologies) and a gradient mobile phase of A 5 mM ammonium acetate
and B methanol. The elution started with 90% A at 0 minutes to 80% at
2 minutes, 65% at 10 minutes, 40% at 12 to 17 minutes, and 90% at 19 minutes.
Flow rate of the mobile phase was 1 ml/min and the flow from the column
was split 1:3 into an ABSciex API4000 triple quadrupole mass spectrometer
equipped with a Turbo Ionspray source operating at 450°C. The column
temperature was maintained at 35°C. The column effluent was monitored at
the following precursor-product ion transitions: m/z 227→185 for RES, m/z
150→107 for IS (APAP), 403→113 for R3G, and 307→227 for R3S with
dwell time of 400 ms for each ion transition. The retention time was about 5
minutes for IS (APAP), about 5.9 minutes for R3G, about 9.2 minutes for R3S,
and about 14.2 minutes for RES. The lower limit of quantification was 2.4 ng/ml
for R3S and 10 ng/ml for R3G and RES.

Noncompartmental Pharmacokinetic Analysis. Pharmacokinetic parameters
of RES, R3G, and R3S were analyzed by noncompartmental analysis with
The area under the plasma concentration-time curve (AUC) was calculated
by using eq. 1 as follows (Cassidy and Houston, 1980):

\[ \text{AUC}_{\text{inf}} = \left( \frac{\text{mean AUC}_{\text{inf, i.v.}}}{\text{mean AUC}_{\text{inf, i.v.}}} \right) \times 100. \]  

Data Analysis for Enzyme Kinetics. All data were initially transformed, and
Eadie-Hofstee (E-H) plots were plotted before nonlinear regression analysis.
The Michaelis-Menten model was fit only to data that showed linear E-H plots.
The following equation (eq. 3) was used to fit the data showing linear E-H plots,
and Michaelis-Menten parameter estimates were determined (Segel, 1993):

\[ v = \frac{V_{\text{max}} + [S]}{K_m + [S]}, \]  

where \( v \) is the rate of the reaction, \( V_{\text{max}} \) is the maximum velocity estimate,
\([S]\) is the substrate concentration, and \( K_m \) is the Michaelis-Menten constant.
The following equation (eq. 3) was used to fit the data exhibiting partial
substrate inhibition profile (Hutzel and Tracy, 2002; Tracy and Hummel, 2004):

\[ v = \frac{V_{\text{max}} + [S]}{K_m + [S] + \left( \frac{[S]^2}{K_I} \right)}. \]  

where \( K_i \) is the partial substrate inhibition constant. Nonlinear regression
was performed with GraphPad Prism for Windows (version 4.03; GraphPad
Software Inc., San Diego, CA).

Statistics. Student’s unpaired \( t \) test was used, with \( P < 0.05 \) set as the
significance level. GraphPad Prism for Windows (version 4.03; GraphPad
Software Inc.) was used to perform statistical analysis.

Results

Noncompartmental Pharmacokinetic Analysis of RES. The concentration-time profile of RES and its metabolites after administration
of RES via the IV route is shown in Fig. 2. RES (15 mg/kg),

The IA data were previously published (Sharan et al., 2012). Both IV
and IA experiments were conducted in parallel under the same
laboratory conditions; therefore, we were able to compare the data.
RES was metabolized into two major metabolites: R3S and R3G.
The results of the noncompartmental pharmacokinetic analysis are
summarized in Table 1.

RES exposure (294.98 ± 137.87 minutes*µM) and half-life
(101.30 ± 43.41 minutes) after IV administration were significantly
lower than its exposure (591.08 ± 167.29 minutes*µM) and half-life
(190.58 ± 69.65 minutes) after IA administration (AUC: \( P = 0.01 \), \( t_{1/2} \):
\( P = 0.04 \)). The bioavailability (\( f_{\text{tot}} \)) of RES after IV administration was
49.9%. The clearance and volume of distribution at steady state of RES
after IV administration were not statistically significantly different
compared with those after IA administration (CL: \( P = 0.05 \), Vss:
\( P = 0.85 \)). Interestingly, it was observed that the exposure of R3G
(2268.35 ± 517.00 minutes*µM) after IV administration of RES increased
significantly compared with R3G exposure (921.23 ± 457.07 minutes*µM)
after IA administration (\( P = 0.004 \)). No significant change was
observed in the exposure of R3S after RES administration by both routes
(\( P = 0.67 \)).

The plasma protein binding of RES, R3G, and R3S in mouse
plasma was found to be 91.95 ± 0.99, 66.75 ± 1.56, and 87.24 ±
4.89% (mean ± SD, \( n = 3 \)) respectively.

In Vitro Pulmonary Metabolism. The glucuronidation of RES
was studied in mouse and human lung fractions. Figure 3A shows the
formation rate of R3G in mouse lung fraction with its Eadie-Hofstee

![Fig. 2. Mean plasma concentration-time profile after administration of IV RES, 15 mg/kg. Data are represented as mean ± S.D. (\( n = 5 \)).](image_url)

### TABLE 1

<table>
<thead>
<tr>
<th></th>
<th>RES 15 mg/kg IA (( n = 5 ))</th>
<th>RES 15 mg/kg IV (( n = 5 ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC0-inf</td>
<td>591.08 ± 167.29(^\mathrm{b})</td>
<td>294.98 ± 137.87(^\mathrm{b})</td>
</tr>
<tr>
<td>CI</td>
<td>118.77 ± 33.36</td>
<td>280.04 ± 158.25</td>
</tr>
<tr>
<td>Vss</td>
<td>37.59 ± 23.70</td>
<td>34.90 ± 20.10</td>
</tr>
<tr>
<td>( t_{1/2} )</td>
<td>190.58 ± 69.65</td>
<td>101.30 ± 43.41(^\mathrm{b})</td>
</tr>
<tr>
<td>R3G</td>
<td>921.23 ± 457.07(^\mathrm{b})</td>
<td>2268.35 ± 517.00(^\mathrm{b})</td>
</tr>
<tr>
<td>R3S</td>
<td>174.94 ± 45.75</td>
<td>157.21 ± 77.77(^\mathrm{b})</td>
</tr>
</tbody>
</table>

\( ^a \) AUC, area under the curve; CI, clearance; R3G, trans-resveratrol-3-O-glucuronide; RES, trans-3,5,4-trihydroxystilbene (trans-resveratrol); \( t_{1/2} \), half-life; Vss, volume of distribution at steady state.

\( ^b \) Denotes statistically significant parameter between the IA versus IV groups, with an unpaired student \( t \) test, and \( P < 0.05 \) considered significant.
E-H plot shown as inset. The R3G profile exhibited partial substrate inhibition. This was determined by fitting the data to the partial substrate inhibition equation

\[ \text{Eadie-Hofstee plots.} \]

(E-H) plot shown as inset. The R3G profile exhibited partial substrate inhibition. This was determined by fitting the data to the partial substrate inhibition equation

The E-H plot showed a hook in the upper quadrant typical of partial substrate inhibition kinetic profile (Fig. 3 inset; eq. 3) (Hutzler and Tracy, 2002). Enzyme kinetic parameters are presented in Table 2. When RES was incubated with 0.1 and 0.5 mg/ml human lung microsomes, no R3G was observed above LOQ (limit of quantitation, 10 ng/ml for R3G) at the end of 60 minutes’ incubation. Therefore, no further RES glucuronidation kinetic studies were performed with human lung microsomes.

Fig. 3, B and C show the formation kinetics of R3S in mouse and human lung fractions with E-H plots as insets respectively. R3S formation in both mouse and human lung fractions showed partial substrate inhibition (Hutzler and Tracy, 2002).

Discussion

RES is known to be extensively metabolized into its conjugates, mainly R3G and R3S (Yu et al., 2002; Meng et al., 2004; Hoshino et al., 2010; Iwuchukwu et al., 2012). Lungs are the third in a series of three potential biotransformation sites (along with the gut and liver) that orally ingested RES must cross before entering the general circulation. First-pass metabolism by gut, liver, and lungs in series can synergistically increase total body clearance of RES. Although the role of gut and liver in the metabolism of RES is known (Miksits et al., 2005; Brill et al., 2006; Iwuchukwu and Nagar, 2008), the contribution of lungs to RES metabolism has not been evaluated. In the present study, the contribution of lungs in the metabolism of RES was evaluated using multiple sites of administration and a single site of sampling design (Cassidy and Houston, 1980) in a mouse model. The in vivo study clearly demonstrated the contribution of lungs in the glucuronidation of RES to R3G in mice. In vivo results were corroborated by in vitro studies in mouse lung fractions.

Because species-dependent differences in metabolism are known, in vitro studies were also conducted in human lung fractions to determine whether reliable extrapolation of data can be made between mice and humans. Interestingly, no significant glucuronidation of RES was observed in human lung fractions, implying that the contribution of pulmonary glucuronidation in the metabolism of RES might be quantitatively less important in humans. The species difference in RES glucuronidation at its 3-OH position can be explained by differential expression of uridine 5′-diphosphoglucuronosyltransferase (UGT) isoforms in mouse and human lungs. RES has been reported to be glucuronidated at its 3-OH position via UGT1A1, UGT1A7, and UGT1A9, with minor contribution from UGT1A6, UGT1A8, UGT1A10, and UGT2B7 (Brill et al., 2006). Ugt1a6 has been shown to be expressed well in mouse lung (Buckley and Klaassen, 2007) and might be responsible for RES glucuronidation in mouse lungs. There are conflicting reports about the presence of UGT enzymes in human lung. UGT1A1 and UGT1A10 have been reported in lung cancer samples (Oguri et al., 2004). Several UGT2B isozymes are reportedly present in human lungs (Turgeon et al., 2001). UGT expression and activity have been reported in the upper respiratory tract but not in lungs in humans (Zheng et al., 2002), which becomes important for inhaled compounds. Other studies have shown low or no UGT expression in normal human lung tissue (Zheng et al., 2002; Somers et al., 2007; Nakamura et al., 2008). In the present study, the absence of R3G formation in human lung fraction is consistent with low or absent expression of UGT isoforms in normal human lung tissue (Nakamura et al., 2008) responsible for RES glucuronidation (Brill et al., 2006).

Sulfation experiments showed that RES is sulfated by both mouse and human lungs. RES sulfation at its 3-OH position has been reported via sulfotransferase (SULT) 1A1, 1A2, 1A3, and 1E1 isoforms (Miksits et al., 2005). Mouse lungs express sul1a1, with very low expression of sul1e1 (Alnouti and Klaassen, 2006). SULT1A1, SULT1A3, SULT1E1, SULT2A1, and SULT1B1 are expressed in human lungs, and SULT1A1, SULT1A3, and
SULT1E1 account for around 80% of all SULTs expressed in human lungs (Riches et al., 2009). Therefore, sul1a1 and sul1e1 in mouse lungs and SULT1A1, SULT1A3, and SULT1E1 in human lungs might be responsible for R3S formation. Steroid sulfatase activity has been reported in both human (Milewich et al., 1983) and mouse lung tissue (Milewich et al., 1984), with the highest activity in microsomal fractions of human lung tissue homogenates (Milewich et al., 1983). Steroid sulfatase can desulfate R3S to give RES locally in the lung cells. This futile cycling of RES/R3S by the combined activity of sulfatase and sulfotransferase enzyme can lead to an increase in the retention of the RES/R3S within the lung. This can be important since RES and R3S both have been shown to have pharmacological activity in vitro (Hoshino et al., 2010).

Transporters, in conjunction with metabolizing enzymes, play an important role in the disposition of drugs and metabolites. R3G and R3S disposition is known to be influenced by transporters. R3G has been shown to be a high affinity substrate for human multidrug resistance protein transporter (MRP) 2 (ABCC2), MRP3 (ABCC3), and human breast cancer resistance protein (BCRP; ABCG2) transporters. Although cellular localization of MRP1, MRP3, and MRP4 transporters is unknown, although cellular distribution and localization of MRP1, MRP2, and BCRP in human lungs are reported. MRP1 is expressed on the basolateral membrane, whereas MRP2 and BCRP are expressed toward the apical membrane in human lungs (Bosquillon, 2010). Although cellular localization of MRP3 and MRP4 transporters is unknown in lungs, they are expressed on the basolateral side in hepatocytes (Zamek-Gliszczynski et al., 2006).

Based on present results and previous reports (Maher et al., 2005; Bosquillon, 2010), a simplified scheme for the disposition of RES, R3S, and R3G in mouse lung cells is proposed (Fig. 4A). RES, administered by the IV route, can diffuse into mouse lung cells and can either get metabolized by sulf enzymes present in the endoplasmic reticulum. Additionally, R3S formed from RES can get further desulfated by sulfatase enzymes in the endoplasmic reticulum to give RES, which can further get glucuronidated to R3G. This R3G can diffuse into the cytoplasm and be transported into the blood by Mrp3 and possibly Mrp1. This correlates well with our observation that even after sulfation of RES in lungs (based on our in vitro results), we did not observe any significant difference in the plasma exposure of R3S when RES was administered by the IV route compared with the IA route. Similarly, a schematic pathway for disposition of RES in human lungs has been proposed (Fig. 4B). RES, when presented to human lung cells, gets sulfated to R3S in the cytoplasm. R3S formed can be eliminated in the pulmonary lumen by Mrp2 and BCRP or into blood by Mrp1 and Mrp4. Additionally, it can be desulfated by steroid sulfatase in the endoplasmic reticulum to give back RES. Since no activity of UGT was observed in human lung tissue, RES formed in endoplasmic reticulum can act as a depot, or it can diffuse back into cytoplasm to again get sulfated to R3S. This futile cycling of RES/R3S can prolong the presence of RES/R3S in human lung tissue.

The pulmonary metabolism of RES can have implications for local tissue levels, as well as systemic concentrations of parent and metabolites. The absence of pulmonary glucuronidation in human lung compared with extensive pulmonary glucuronidation in mouse lungs is a possible reason for the observed difference in the pharmacokinetics of RES in rodents versus humans. In rodents, R3G has been observed as the quantitatively major metabolite (Juan et al., 2010b; Colom et al., 2011; Iwuchukwu et al., 2012; Sharan et al., 2012) compared with R3S in humans (Boocock et al., 2007; Brown et al., 2010).

Our results might have implications in the role of RES as a cancer chemopreventive in the lung. As a substrate for SULTs, RES might interfere with the metabolism of cigarette-smoke toxicants. For example, sulfation of benzo(a)pyrene-7,8-dihydrodiol has been suggested to be a detoxification pathway for benzo[a]pyrene-7,8-dione by limiting its ability to undergo redox cycling (Zhang et al., 2012a). Also, increased RES or R3S in the lung can lead to enhanced quenching of unstable free radicals and can lead to reduced DNA damage by reactive oxygen species, which are known to be produced by cigarette-smoke toxicants. Interestingly, RES and R3S have been shown to have comparable ability to quench the 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical (Hoshino et al., 2010).

In summary, significantly higher R3G exposure was observed in mouse when RES was administered by the IV route compared with the IA route. Extensive glucuronidation and sulfation of RES were observed in mouse lung fractions. Human lung fractions on the other hand showed only sulfation of RES and a potential for futile cycling of RES/R3S in lung, which can have pharmacological significance. In conclusion, pulmonary metabolism of RES might play an important role in the pharmacokinetics and activity of RES. 

### Table 2

<table>
<thead>
<tr>
<th>Substrate</th>
<th>Conjugation Product</th>
<th>Protein Source</th>
<th>Vmax (pmol/min/mg)</th>
<th>Km (μM)</th>
<th>Ki (μM)</th>
<th>Goodness of Fit (r²)</th>
<th>Type of Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td>RES</td>
<td>R3G</td>
<td>Mouse lung S9</td>
<td>32.40 ± 13.05</td>
<td>7.34 ± 1.60</td>
<td>6632 ± 1198</td>
<td>0.93</td>
<td>Partial substrate inhibition</td>
</tr>
<tr>
<td>RES</td>
<td>R3S</td>
<td>Mouse lung S9</td>
<td>7.05 ± 0.28</td>
<td>2.69 ± 0.45</td>
<td>2021 ± 717.6</td>
<td>0.96</td>
<td>Partial substrate inhibition</td>
</tr>
<tr>
<td>RES</td>
<td>R3S</td>
<td>Human lung S9</td>
<td>16.15 ± 0.48</td>
<td>4.45 ± 0.79</td>
<td>23,238 ± 7305</td>
<td>0.95</td>
<td>Partial substrate inhibition</td>
</tr>
</tbody>
</table>

Km, partial substrate inhibition constant; Km, the Michaelis-Menten constant; RES, resveratrol-3-sulfate; R3G, trans-resveratrol-3-O-glucuronide; R3S, trans-resveratrol-3-sulfate; RES, res-3,5,4′-trihydroxystilbene (trans-resveratrol).

**Downloaded from dmd.aspetjournals.org on January 20, 2018**
Fig. 4. Proposed schematic representation of RES metabolism in (A) mouse lung cells and (B) human lung cells. Solid arrows represent pathways based on results in this manuscript and published literature reports for metabolism and/or transport of RES, R3S, and R3G. Transporters followed by "?" indicates that the role of these transporters has not been established for transport of R3S and R3G but is hypothesized based on literature detailed in the Discussion.
References


Gastroenterology 81:1006–1011.


Address correspondence to: Dr. Swati Nagar, Temple University School of Pharmacy, 3307 N Broad Street, Philadelphia PA 19140. E-mail: swati.nagar@temple.edu.